Sort
53,477 grants matching “addiction”
5/24 Healthy Brain and Child Development National Consortium
$2,886,901Patricia Ellen Grant · Boston Children'S Hospital · U01 · FY2024 · DA
Combining Pregabalin with Lofexidine: Can it Increase the Success of Transition to Naltrexone?
$2,884,653Kyle Matthew Kampman · University Of Pennsylvania · UH3 · FY2023 · DA
Pain, Opioids, and ESRD risk reduction with Mindfulness and Buprenorphine (POEM-B): A 3-arm multi-site randomized trial in hemodialysis patients
$2,883,251David M Charytan · New York University School Of Medicine · U01 · FY2019 · DK
4/6 HBCD Prenatal Experiences and Longitudinal Development (PRELUDE) Consortium
$2,881,039Stephanie L Merhar · Cincinnati Childrens Hosp Med Ctr · U01 · FY2024 · DA
NCATS ASPIRE REDUCTION-TO-PRACTICE CHALLENGE
$2,875,000 · N01 · FY2020 · TR
Transgenic Resources for Neuroscience Research
$2,871,501James Pickel · National Institute Of Mental Health · ZIC · FY2015 · MH
Disrupted Adenovirus Serotype 5-based Anti-cocaine Vaccine
$2,868,677Ronald G Crystal · Weill Medical Coll Of Cornell Univ · U01 · FY2012 · DA
NIDA Clinical Trials Network: New York Node
$2,867,419Jennifer McNeely · New York University School Of Medicine · UG1 · FY2023 · DA
Pragmatic Trial of Acupuncture for Chronic Low Back Pain in Older Adults
$2,864,772Karen J Sherman · Kaiser Foundation Research Institute · UH3 · FY2021 · AT
Center for Adolescent Reward, Rhythms and Sleep (CARRS)
$2,860,596Colleen A McClung · University Of Pittsburgh At Pittsburgh · P50 · FY2025 · DA
TREATMENT OF ADDICTIONS--BIOLOGICAL CORRELATES
$2,856,886Rockefeller University · P60 · FY2003 · DA
Center for Dissemination and Implementation At Stanford (C-DIAS)
$2,852,498Mark P. McGovern · Stanford University · P50 · FY2022 · DA
JCOIN Phase II Coordination and Translation Center
$2,850,000Faye S Taxman · George Mason University · U2C · FY2025 · DA
NeuroTech Harbor: Seedling Cohort 3
$2,850,000Sridevi V. Sarma · Johns Hopkins University · U54 · FY2025 · EB
Pain Reduction and Opioid MedIcation Safety in ESRD (PROMISE) study
$2,847,465Manisha Jhamb · University Of Pittsburgh At Pittsburgh · U01 · FY2019 · DK
Treatment for Complex Patients: Continuing and Extended Care
$2,847,074Joseph R Guydish · University Of California, San Francisco · P50 · FY2011 · DA
University of Illinois at Chicago Hemodialysis Opioid Prescription Effort (HOPE) Clinical Center
$2,845,360Michael J. Fischer · University Of Illinois At Chicago · U01 · FY2019 · DK
The RADAR cohort study of multilevel Influences on HIV and substance use
$2,844,399Brian Mustanski · Northwestern University At Chicago · U01 · FY2025 · DA
Neuroimaging and neuromodulation of preclinical models of substance use disorders
$2,844,296Yihong Yang · National Institute On Drug Abuse · ZIA · FY2025 · DA
Novel opioids that protect against oral overdose and disrupt the progression to misuse, abuse, and addiction
$2,841,799Thomas E Jenkins · Elysium Therapeutics, Inc. · R01 · FY2018 · DA
Novel Medication Approaches for Substance Abuse
$2,840,235New York State Psychiatric Institute · P50 · FY2004 · DA
Clinical Genomics and Experimental Therapeutics
$2,830,248Falk Lohoff · National Institute On Alcohol Abuse And Alcoholism · ZIA · FY2020 · AA
Multi Site Randomized Trial of a GLP-1/GIP Receptor Agonist for Smoking Cessation
$2,828,440Christian S Hendershot · University Of Southern California · U01 · FY2025 · DA
Development of Specific Mu Opioid Receptor Antagonists to Reverse the Acute and Chronic Toxicity of Fentanyls
$2,824,374Yan Zhang · Virginia Commonwealth University · UG3 · FY2022 · DA
Integrative genetics of behavior with high throughput technologies
$2,824,057David Goldman · Alcohol Abuse And Alcoholism · Z01 · FY2007 · AA